Patrys Limited (PAB), a publicly listed company headquartered in Melbourne, is dedicated to advancing novel antibody therapeutics for oncology. Central to their efforts is the deoxymab platform, centred around an antibody known as 3E10. Patrys has been at the forefront of developing groundbreaking therapies for cancer treatment. Recently, at an international conference, the company highlighted the potential of Deoxymabs not only in oncology but also in treating autoimmune diseases, marking a significant expansion of their therapeutic applications.